Heron Therapeutics(US:HRTX)2026-02-26 14:32Financial Data and Key Metrics Changes - For the full year 2025, the company generated approximately $155 million in total net revenues and delivered adjusted EBITDA of $14.7 million, exceeding the previously communicated guidance range of $9 million to $13 million [6][20] - Gross margin for the year was approximately 73%, reflecting continued improvements in cost discipline and product mix [6] Business Line Data and Key Metrics Changes - The acute care franchise increased more than 57% year-over-year in Q4 2025, with ZYNRELEF delivering 48% net revenue growth compared to Q4 2024, and APONVIE growing 97% over the same period [7][13] - Oncology franchise generated just over $105 million in net revenue for the full year 2025, representing a modest 7.8% decline compared to 2024, primarily due to the planned wind down of SUSTOL [10] Market Data and Key Metrics Changes - Acute care net sales were $16.3 million in Q4 2025, up from $12.3 million in Q3 2025, driven primarily by ZYNRELEF and APONVIE [13] - The company expects to see continued growth in unit volume for the CINV franchise, despite anticipated price erosion [25] Company Strategy and Development Direction - The strategy for 2026 and beyond includes accelerating the expansion of the commercial team in key markets, focusing on areas with strong success indicators and favorable reimbursement dynamics [8] - The company plans to increase commercial investments, which may temporarily moderate EBITDA growth, but are expected to drive meaningful growth in top-line revenue [8][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the commercial inflection seen in Q4 2025 continuing into 2026, with a focus on maintaining EBITDA positivity while making targeted commercial investments [21] - The successful completion of financing has eliminated previous capital structure overhangs, providing the company with the financial flexibility needed for growth [21] Other Important Information - The company is advancing the prefilled syringe presentation for ZYNRELEF, with potential FDA approval anticipated in mid to late 2027 [9] - The inclusion of APONVIE in the newly released fifth consensus guidelines for the management of PONV is expected to support long-term utilization [7][16] Q&A Session Summary Question: Expectations for the CINV franchise and the NOPAIN Act's impact on ZYNRELEF - Management expects unit volume growth for the CINV franchise, with some price erosion, while the NOPAIN Act is anticipated to be a strong tailwind for ZYNRELEF [25][26] Question: Rollout status of the Vial Access Needle (VAN) and its impact on sales - The VAN rollout went smoothly, removing preparation challenges, and the company plans to continue leveraging this success for the prefilled syringe launch [30][32] Question: Update on the Slayback litigation regarding CINVANTI - The company is confident in its case and expects a decision from Judge Bryson before the 30-month stay [37] Question: Awareness efforts regarding the NOPAIN Act - The company is expanding its team to enhance awareness and understanding of the NOPAIN Act among providers, which is crucial for reimbursement [40] Question: Timeline for the impact of new consensus guidelines on PONV growth - The guidelines are expected to have a significant impact within 6 to 9 months as they are integrated into order sets and protocols [45][51]